Tag: monoclonal antibodies (mas) market growth

Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

2024-2033 Forecast: What is the Projected Growth Rate for the Oral Biologics & Biosimilar Drugs Market?

The market size for oral biologics and biosimilar drugs has seen a tremendous growth over the last few years. From $5.94 billion in 2023, it is projected to increase to $7.19 billion in 2024, demonstrating a compound annual growth rate (CAGR) of 21.0%. This significant upsurge throughout the historical period can be linked to the increased occurrence of chronic illnesses, the heightened awareness of oral biologics, an upswing in patent expirations, and a growing requirement for biosimilars.

The size of the oral biologics & biosimilar drugs market is anticipated to witness a substantial growth spurt in the forthcoming years, reaching a staggering $13.32 billion in 2028 with a compound annual growth rate (CAGR) of 16.7%. This projected growth rate during the forecast period can be credited to elements such as targeted therapy, an increased emphasis on preventive medicine, heightened healthcare expenditure, and the aging population. The forecast period is also expected to present significant trends such as advancements in oral delivery technology, the introduction of orally administered biologics, innovation in biosimilars, and a patient-centric approach to care.

Claim Your Free Sample of the Global Oral Biologics & Biosimilar Drugs Market Report Today!

https://www.thebusinessresearchcompany.com/sample.aspx?id=3792&type=smp

What Are the Main Drivers Behind the Growth of the oral biologics & biosimilar drugs Market?

The oral biologics and biosimilar market is set to grow essentially due to the accelerating prevalence of chronic diseases such as arthritis, asthma, and cancer. Risk factors further contributing to such diseases include longer working hours, limited exercise, and subpar dietary and drinking routines. To combat these chronic conditions, biologics are progressively employed, acting by triggering the immune system to counter and eradicate cancer cells. A United Nations report predicts that by 2030, chronic diseases will account for 70% of global deaths while the worldwide percentage of chronic diseases is predicted to hit 60%. Subsequently, the escalating prevalence of chronic diseases is forecasted to surge the demand for biologics and biosimilars, hence, fueling the oral biologics & biosimilar drugs market expansion.

What Are the Primary Segments of the Oral Biologics & Biosimilar Drugs Market?

1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors

2) By Disease: Asthma, Crohn’s Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others

3) By Molecule Type: Vaccines, Proteins & Peptides, Monoclonal Antibodies, Other Molecule Types

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Which Trends Are Revolutionizing the Oral Biologics & Biosimilar Drugs Market?

The current progression in the oral biologics and biosimilar market is the development of novel insulin biosimilars. The major contributors in the oral biologics and biosimilar market are endorsing resources into producing an equivalent of insulin. This, in turn, is fostering rivalry amongst different biosimilar manufacturers. For instance, Eli Lilly and Company, a US firm manufacturing oral biologics and biosimilar drugs, introduced their new insulin glargine biosimilar, Rezvoglar (insulin glargine-aglr), in April 2023. Insulin glargine products like these are commonly used for managing glucose levels in type 1 diabetes patients – adults, children, and infants, as well as type 2 diabetes adults.

Order Now for Fast Delivery of Your Oral Biologics & Biosimilar Drugs Market Report!

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilar-drug-global-market-report

Which Geographical Regions Are Pioneering Growth in the Oral Biologics & Biosimilar Drugs Market?

North America was the largest region in the oral biologics and biosimilar drugs market in 2023. The Middle East is expected to be the fastest growing region in the oral biologics & biosimilar drugs market report during the forecast period. The regions covered in the oral biologics & biosimilar drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The Oral Biologics & Biosimilar Drugs Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the oral biologics & biosimilar drugs market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Oral Biologics & Biosimilar Drugs Market Include

1. Oral Biologics & Biosimilar Drugs Market Executive Summary

2. Oral Biologics & Biosimilar Drugs Market Segments

3. Oral Biologics & Biosimilar Drugs Market Size And Template Market Growth Rate

4. Key Oral Biologics & Biosimilar Drugs Market Trends

5. Major Oral Biologics & Biosimilar Drugs Market Drivers

……

25. Key Mergers And Acquisitions In The Oral Biologics & Biosimilar Drugs Market

26. Top Oral Biologics & Biosimilar Drugs Companies

27. Oral Biologics & Biosimilar Drugs Market Opportunities And Strategies

28. Oral Biologics & Biosimilar Drugs Market, Conclusions And Recommendations

29. Appendix

Discover Related Reports by The Business Research Company:

Dental Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/dental-services-global-market-report

Dental Practice Management Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/dental-practice-management-global-market-report

Dental X-Ray Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/dental-x-ray-equipment-global-market-report

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

What is the Anticipated CAGR of the Monoclonal Antibodies (MAs) Market Over the 2024-2033 Forecast Period?

The market size of monoclonal antibodies (mabs) has seen a considerable increase in recent years. It is projected to inflate from $234.37 billion in 2023 to $261.66 billion in 2024, experiencing a compound annual growth rate (CAGR) of 11.6%. The surge in growth during the historical period is linked to the widespread occurrence of chronic illnesses, increased investment in research and development, rising awareness about mabs, and an increasing elderly population.

The market for monoclonal antibodies (mabs) is anticipated to experience swift expansion in the coming years, with projections seeing it reaching $424.24 billion by 2028, growing at a compound annual growth rate (CAGR) of 12.8%. This growth over the forecast period can be tied to factors like the rise in therapeutic indications, personalized medicine, biosimilars and generics, combination therapies, pandemic readiness, and investments in biopharmaceuticals. Key trends shaping the market during this forecast period encompass advances in immunotherapy, the rise of subcutaneous administration and formulations, next-generation antibodies, digital health integration, and progress in biotechnology.

Claim Your Free Sample of the Global Monoclonal Antibodies (MAs) Market Report Today!

https://www.thebusinessresearchcompany.com/sample.aspx?id=2554&type=smp

What Are the Driving Forces Behind the Growth of the monoclonal antibodies (mas) Market?

The availability of biosimilar monoclonal antibodies at lower costs is propelling the expansion of the monoclonal antibody market. Their objective is to restrain the escalating healthcare costs while dealing with the economic strain from both patients and governments, all aimed at minimizing the expenses on drugs and broadening the scope of treatment accessibility. Biosimilars are medications fabricated to mimic the characteristics of already approved biological drugs. They come at 20%-25% lower prices than the original biologic drug. The rationale behind these pocket-friendly prices is the fewer clinical trials required for biosimilars as opposed to the original biologics. Particularly in India, a freshly introduced biosimilar policy named ‘Guidelines on Similar Biologics’, conceived by the Central Drugs Standard Control Organization (CSDCO), is anticipated to significantly uplift the Indian biosimilar drug industry.

What Are the Core Segments of the Monoclonal Antibodies (MAs) Market?

1) By Source: Murine, Chimeric, Humanized, Human

2) By Application: Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAs), Neuropharmacological, Cardiovascular And Cerebrovascular, Other Applications

3) By End Users: Hospitals, Private Clinics, Research Institute

What Are the Key Innovations Reshaping the Monoclonal Antibodies (MAs) Market?

In the recent past, the monoclonal antibody industry has seen numerous strategic initiatives. Industry-leading companies are strategically acquiring small and medium-sized businesses to diversify their product and service offerings. Vendors utilise strategic alliances, acquisitions, and business agreements to enhance their existing product range and geography. For instance, Sanofi S.A., a pharmaceutical and healthcare firm from France known for its drug discovery, development, manufacturing, and marketing, revealed a strategic alliance with Seagen Inc., an American pharmaceutical firm renowned for creating and marketing innovative, potent cancer treatments based on monoclonal antibodies, in March 2022. This partnership will utilise the exclusive monoclonal antibody (mAb) and antibody-drug conjugate (ADC) technologies of Seagen and Sanofi to design, develop, and sell ADCs for up to three cancer targets. Additionally, Boehringer Ingelheim, a German pharmaceutical company focused on research, announced a collaboration with MabGenesis, Inc., a Japanese biopharmaceutical company leading the development of therapeutic monoclonal antibody drugs for human diseases. This partnership between Boehringer Ingelheim and MabGenesis will result in the discovery and development of novel therapeutic monoclonal antibodies for a variety of diseases and strategic research and development plans. Companies in the sector are increasingly restructuring their portfolios and exploring profitable non-organic growth potentialities. Corporate balance sheets strengthening, liquid debt markets, and continued global favourable interest rates are also driving interest in mergers and acquisitions.

Order Now for Fast Delivery of Your Monoclonal Antibodies (MAs) Market Report!

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

What Regions Are Influencing the Dynamics of the Monoclonal Antibodies (MAs) Market?

North America was the largest region in the monoclonal antibodies (MAbS) market in 2023. The regions covered in the monoclonal antibodies (MABS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The Monoclonal Antibodies (MAs) Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the monoclonal antibodies (mas) market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Monoclonal Antibodies (MAs) Market Include

1. Monoclonal Antibodies (MAs) Market Executive Summary

2. Monoclonal Antibodies (MAs) Market Segments

3. Monoclonal Antibodies (MAs) Market Size And Template Market Growth Rate

4. Key Monoclonal Antibodies (MAs) Market Trends

5. Major Monoclonal Antibodies (MAs) Market Drivers

……

25. Key Mergers And Acquisitions In The Monoclonal Antibodies (MAs) Market

26. Top Monoclonal Antibodies (MAs) Companies

27. Monoclonal Antibodies (MAs) Market Opportunities And Strategies

28. Monoclonal Antibodies (MAs) Market, Conclusions And Recommendations

29. Appendix

Discover Related Reports by The Business Research Company:

Biosimilar Monoclonal Antibodies Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodie-global-market-report

Conjugated Monoclonal Antibodies Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/conjugated-monoclonal-antibodie-global-market-report

Biosimilars Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

According to The Business Research Company’s Monoclonal Antibodies (MAs) Global Market Report 2024, the monoclonal antibodies (MAs) market is expected to show promising growth in the forecast period.

The monoclonal antibodies (mAbs) market has witnessed remarkable growth in recent years, indicating a promising trajectory ahead. Here are some key figures and insights:

• The market size surged from $234.37 billion in 2023 to $261.66 billion in 2024, showcasing a compound annual growth rate (CAGR) of 11.6%.
• Factors attributing to this growth include the prevalence of chronic diseases, escalating investments in research and development, heightened awareness regarding mAbs, and the expanding elderly population.

Anticipating Future Trends

Looking ahead, the market is projected to continue its upward surge, reaching a staggering $424.24 billion by 2028, boasting a CAGR of 12.8%. Here’s what to expect in the forecast period:

• Expanding therapeutic indications and personalized medicine are poised to drive market growth.
• The rise of biosimilars and generics, coupled with innovative combination therapies, is expected to reshape the landscape.
• Trends such as immunotherapy advancements, subcutaneous administration, and digital health integration are likely to dominate the market.

Rising Popularity Of Cost-Efficient Biosimilar Monoclonal Antibodies Fuels Market Growth

Understanding Biosimilars

The burgeoning popularity of cost-efficient biosimilar monoclonal antibodies stands as a significant driver behind the market’s expansion. Key points to note include:

• Biosimilars aim to alleviate healthcare costs and enhance medication accessibility.
• These pharmaceuticals mimic the properties of approved biological drugs, offering a more economical alternative.
• Notably, biosimilar monoclonal antibodies cost 20%–25% less than their original counterparts.

Indian Biosimilar Policy

India’s ‘Guidelines on Similar Biologics’ herald a substantial boost to the biosimilar drugs industry, further propelling market growth.

View More On The Monoclonal Antibodies (MAs) Market Report 2024 – https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

Innovative Technologies Enhancing Competitiveness

Embracing RenMice

Major players in the monoclonal antibodies market are leveraging innovative technologies like RenMice to gain a competitive edge:

• RenMice facilitates the exploration of various antibody-based therapies, including bispecific antibodies and nanobodies.
• Biocytogen Pharmaceuticals’ RenMice series exemplifies groundbreaking advancements in fully human antibody mice and TCR mice, fostering innovation.

FDA’s Regulatory Support Bolstering Therapeutics Market

Accelerating Approvals

The FDA’s regulatory support plays a pivotal role in bolstering the monoclonal antibody therapeutics market:

• Accelerated approvals for novel treatments, such as avelumab and TECENTRIQ, underscore the agency’s commitment to advancing healthcare.

Segmentation Insights: Understanding Market Dynamics

Diverse Segmentation

The monoclonal antibodies market is segmented across various dimensions, offering nuanced insights into its dynamics:

1. By Source: Murine, Chimeric, Humanized, Human
2. By Application: Anti-Cancer, Immunological, Anti-Infective, Neuropharmacological, Cardiovascular, and more.
3. By End Users: Hospitals, Private Clinics, Research Institutes

North America Leads the Way

Regional Dominance

North America emerged as the frontrunner in the monoclonal antibodies market in 2023, underlining the region’s prominence in driving industry growth.

In conclusion, the monoclonal antibodies market continues to evolve, driven by technological innovations, regulatory support, and a growing demand for cost-effective therapies. As we navigate through dynamic landscapes, collaborations and advancements will be instrumental in unlocking the full potential of this burgeoning sector.

Request A Sample Of The Global Monoclonal Antibodies (MAs) Market Report 2024:

https://www.thebusinessresearchcompany.com/sample_request?id=2554&type=smp